Acea Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4955 Directors Pl, San Diego, California...Website
www.aceatherapeutics.comRevenue
$8.6 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Acea Therapeutics
ACEA Therapeutics is dedicated to developing and delivering innovative treatments aimed at improving the lives of patients. The company focuses on a range of medical conditions, including COVID-19, lymphoma, lung cancer, and lupus. Their product pipeline includes several candidates such as Olgotrelvir, Abivertinib, and AC0058. ACEA Therapeutics serves both patients and physicians, emphasizing a commitment to health innovation.Explore more
Acea Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acea Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Acea Therapeutics recently announced quarterly report
Click to see if Acea Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Acea Therapeutics
Website visits: Recent activity has been detected on your website
Check if Acea Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Acea Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Acea Therapeutics launches new products
Funding: Get notified immidiatlly once Acea Therapeutics has new funding data
Check out if Acea Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Acea Therapeutics
Compare insights from companies similar to Acea Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Acea Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Acea Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Acea Therapeutics.
Acea Therapeutics financials insights
Gather financial insights about Acea Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Acea Therapeutics Tech Stack
A closer look at the technologies used by Acea Therapeutics
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions (M&A)
Funding
Acea Therapeutics has received an SBA PPP loan for $350,000-1 million from Bank of America.
Funding
Acea Therapeutics News & Media
Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region
PALO ALTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that that it has entered into a Memorandum of Understanding (MOU) for collaboration agreement with ACEA, a China-based company focused on the development of innovative treatments for high unSorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has completed the acquisition of ACEA Therapeutics Inc. (“ACEA”).Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA ...
ACEA’s major assets include: Abivertinib (in oral capsule form), a next generation, dual EGFR mutant and BTK inhibitor (BTKi) with a completed NSCLC registrational/Phase 3 trial, Phase 1 B-cell lymphoma study, and ongoing Phase 2 trials in COVID-19 patients with ARDS, and Phase 2 studies for prostate cancer, systemic lupus erythematosus and the ultra-orphan indication of hairy cell leukemia.AC0058, a brain-penetrating, next generation BTK inhibitor in a Phase 1b Lupus trial and IND-enabling studSorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) have entered into a binding term sheet for an exclusive license to ACEA’s Abivertinib across all indications for all territories outside of China. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acea Therapeutics
Sign Up For FreeTo access detailed company insights
ACEA Therapeutics is dedicated to developing and delivering innovative treatments aimed at improving the lives of patients. The company focuses on a range of medical conditions, including COVID-19, lymphoma, lung cancer, and lupus. Their product pipeline includes several candidates such as Olgotrelvir, Abivertinib, and AC0058. ACEA Therapeutics ser... Read More
